$AQST earnings report

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update. AlphAI read Aquestive Therapeutics's third quarter 2026 filing as mixed. 2 quarters are on record below.

third quarter 2026

AlphAI · Earnings readAQST · third quarter 2026 · ended September 30, 2026

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

→Mixed quarter

Third-quarter revenue declined 41% to $7.6 million and non-GAAP adjusted EBITDA loss widened to $12.2 million, while the Anaphylm NDA resubmission was accepted with a March 16, 2027 PDUFA goal date and full-year 2026 guidance was maintained.

Revenue
$7.6M
41% decrease y/y
Manufacture and supply revenue
$6.7M
Gross margin · GAAP
52 %
EPS · GAAP
$0.13 for both basic and diluted loss
full-year 2026 outlook
$46 to $50 (in millions)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues, three months ended September 30, 2026GAAP$7.6M–41% decrease
Manufacture and supply revenue, three months ended September 30, 2026GAAP$6.7M––
License and royalty revenue, three months ended September 30, 2026GAAP$800K––
Manufacture and supply expense, three months ended September 30, 2026GAAP$3.61M––
Gross Margin on total revenue, three months ended September 30, 2026GAAP52 %––
Non-GAAP adjusted manufacture and supply expenses, three months ended September 30, 2026non-GAAP$3.40M––
Non-GAAP Gross Margin on total revenue, three months ended September 30, 2026non-GAAP55 %––
Research and development expenses, three months ended September 30, 2026GAAP$4.3M––
Non-GAAP adjusted research and development expenses, three months ended September 30, 2026non-GAAP$3.92M––
Selling, general and administrative expenses, three months ended September 30, 2026GAAP$14.2M––
Non-GAAP adjusted selling, general and administrative expenses, three months ended September 30, 2026non-GAAP$12.43M––
Total costs and expenses, three months ended September 30, 2026GAAP$22.03M––
Non-GAAP adjusted costs and expenses, three months ended September 30, 2026non-GAAP$19.74M––
Loss from operations, three months ended September 30, 2026GAAP−$14.47M––
Interest expense, three months ended September 30, 2026GAAP−$1.84M––
Interest expense related to royalty obligations, three months ended September 30, 2026GAAP−$973K––
Interest expense related to the sale of future revenue, three months ended September 30, 2026GAAP−$62K––
Interest income and other income, net, three months ended September 30, 2026GAAP$853K––
Net loss before income taxes, three months ended September 30, 2026GAAP−$16.50M––
Net loss, three months ended September 30, 2026GAAP$16.5M––
Basic and diluted loss per share, three months ended September 30, 2026GAAP$0.13 for both basic and diluted loss per share––
Weighted average common shares outstanding, basic and diluted, three months ended September 30, 2026GAAP125,548,783 (in shares)––
Non-GAAP adjusted EBITDA loss, three months ended September 30, 2026non-GAAP$12.2M––
Non-GAAP adjusted EBITDA excluding Non-GAAP adjusted R&D expenses, three months ended September 30, 2026non-GAAP−$8.27M––
Revenues, nine months ended September 30, 2026GAAP$35.82M––
Gross Margin on total revenue, nine months ended September 30, 2026GAAP69 %––
Loss from operations, nine months ended September 30, 2026GAAP−$26.90M––
Net loss, nine months ended September 30, 2026GAAP−$47.42M––
Basic and diluted loss per share, nine months ended September 30, 2026GAAP$(0.38) (in dollars per share)––
Non-GAAP adjusted EBITDA, nine months ended September 30, 2026non-GAAP−$19.15M––
Non-GAAP Gross Margin on total revenue, nine months ended September 30, 2026non-GAAP71 %––

Segments

SegmentRevenueq/qy/y
Manufacture and supply revenueDecreases in Suboxone revenues due to timing of product orders, partially offset by higher Ondif revenues.$6.7M––
License and royalty revenueLower estimated royalty revenues.$800K––

full-year 2026 outlook

  • Revenue$46 to $50 (in millions)
  • NoteNon-GAAP adjusted EBITDA loss (in millions) $35 to $30

What drove it

  • The 41% decrease in total revenues was primarily driven by the quarterly fluctuation of Suboxone product orders.
  • The Company manufactured approximately 26 million doses in the third quarter 2026, compared to approximately 44 million doses in the third quarter 2025.
  • On a year-to-date basis through September, the Company manufactured approximately 107 million doses in 2026 compared to approximately 108 million doses in the same period in 2025.
  • Research and development expense declined primarily due to lower share-based compensation, partially offset by higher clinical trial costs from the human factors validation study and PK study completed for the Anaphylm NDA resubmission.
  • Selling, general and administrative expense declined primarily due to lower legal fees of approximately $1.5 million, lower commercial spending of approximately $1.4 million, and lower regulatory expenses related to Anaphylm of approximately $0.6 million.
  • In October 2026, Aquestive granted Eton Pharmaceuticals, Inc. exclusive U.S. commercialization rights to Libervant and received a $10 million upfront payment.

Concerns

  • Revenue fell to $7.6 million from $12.8 million as Suboxone product ordering timing reduced manufacture and supply revenue.
  • Non-GAAP adjusted EBITDA loss widened to $12.2 million from $8.6 million.
  • Net loss increased to $16.5 million from $15.4 million.
  • Anaphylm approval remains subject to FDA review, with a PDUFA goal date of March 16, 2027.
  • The filing identifies risks including eroding market share for Suboxone® and potential FDA requests for additional information, analyses, studies or inspections for Anaphylm.

What to watch

  • FDA review of the Anaphylm Class 2 NDA resubmission ahead of the March 16, 2027 PDUFA goal date.
  • Expected Health Canada submission in Q4 2026 and planned European Union filing in Q1 2027 for Anaphylm.
  • Additional AQST-108 clinical work expected to begin in the first quarter of 2027.
  • Final FDA action for Libervant patients twelve years of age and older, with a PDUFA goal date of March 23, 2027.
  • FDA review of the Type 9 NDA for Libervant patients six to eleven years of age, with a PDUFA goal date of March 29, 2027.
  • Execution of Eton Pharmaceuticals’ U.S. commercialization of Libervant and potential contingent milestone and royalty payments.

Balance sheet and cash flow

  • Cash and cash equivalents were $90.3 million as of September 30, 2026.
  • Cash and cash equivalents were $ 90,349 (In thousands) at September 30, 2026, compared with $ 121,169 (In thousands) at December 31, 2025.
  • Debt, current was $ 33 (In thousands) at September 30, 2026, compared with $ 9,994 (In thousands) at December 31, 2025.
  • Debt, long-term, net was $ 50,757 (In thousands) at September 30, 2026, compared with $ 27,519 (In thousands) at December 31, 2025.
  • Royalty obligations, net were $ 28,702 (In thousands) at September 30, 2026, compared with $ 25,941 (In thousands) at December 31, 2025.
  • Liability related to the sale of future revenue, net was $ 61,192 (In thousands) at September 30, 2026, compared with $ 62,023 (In thousands) at December 31, 2025.

Analysis

Aquestive reported a weaker third quarter on its existing commercial business. Total revenues decreased to $7.6 million from $12.8 million, a 41% decrease that the company attributed primarily to quarterly fluctuation in Suboxone product orders. Manufacture and supply revenue decreased to $6.7 million from $11.5 million, while license and royalty revenue decreased to $0.8 million from $1.0 million. Manufacturing volume was approximately 26 million doses, compared with approximately 44 million doses in the prior-year quarter.

The lower revenue base pressured profitability. GAAP gross margin on total revenue was 52%, compared with 65%, and non-GAAP gross margin was 55%, compared with 67%. The operating loss was $(14,469) (In thousands), compared with $(11,479) (In thousands). Net loss was $16.5 million, or $0.13 for both basic and diluted loss per share, compared with $15.4 million, or $0.14 for both basic and diluted loss per share. Non-GAAP adjusted EBITDA loss widened to $12.2 million from $8.6 million.

Cost control partly offset the revenue decline. Research and development expenses decreased to $4.3 million from $4.5 million, reflecting lower share-based compensation partly offset by higher clinical trial costs for Anaphylm studies. Selling, general and administrative expenses decreased to $14.2 million from $15.3 million, driven by lower legal fees, commercial spending and Anaphylm regulatory expenses, partly offset by higher personnel, share-based compensation, consulting and outside-services expenses. For the nine months ended September 30, 2026, revenues were $35,822 (In thousands) versus $31,530 (In thousands), while net loss was $(47,417) (In thousands) versus $(51,924) (In thousands).

The central business development was FDA acceptance of the Anaphylm NDA resubmission as a Class 2 response, with a March 16, 2027 PDUFA goal date. The company is progressing launch preparation, expects a Health Canada submission in Q4 2026 and plans an EU filing in Q1 2027. In a separate commercial development, Eton received exclusive U.S. commercialization rights to Libervant, paid Aquestive a $10 million upfront payment, and may generate up to $47.5 million in contingent regulatory and sales-based milestones plus mid-teens royalties on net sales. Aquestive remains the exclusive manufacturer and supplier under a 20-year supply agreement.

Liquidity stood at $90.3 million of cash and cash equivalents as of September 30, 2026, compared with $ 121,169 (In thousands) at December 31, 2025. Long-term debt, net was $ 50,757 (In thousands), and the liability related to the sale of future revenue, net was $ 61,192 (In thousands). Full-year 2026 guidance was unchanged at total revenue of $46 to $50 (in millions) and non-GAAP adjusted EBITDA loss of $35 to $30 (in millions).

Management, verbatim

With a PDUFA goal date of March 16, 2027, we believe we have a clear path to making Anaphylm available to patients and caregivers, if approved.

Daniel Barber, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Previous-period outlook was not provided, so comparison of actual results with prior guidance is unavailable.
  • Quarterly operating cash flow was not reported.
  • Quarterly free cash flow was not reported.
  • Share repurchases, dividends and other capital-return activity were not reported.
  • Total debt as a single line item was not reported; current debt and long-term debt, net were reported separately.
  • A GAAP tax rate was not reported.
  • Quarter-over-quarter comparisons were not reported for the financial metrics.
  • Separate reported business-segment revenue beyond manufacture and supply revenue and license and royalty revenue was not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readAQST · second quarter 2026 · ended June 30, 2026

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

→Mixed quarter

Revenue increased 38% to $13.8 million and non-GAAP adjusted EBITDA loss improved to $5.2 million, but GAAP net loss widened to $22.9 million following an $11.7 million loss on extinguishment of debt. The Company maintained its 2026 outlook and remains on track for an Anaphylm NDA resubmission in Q3 2026.

Revenue
$13.8M
38% y/y
Manufacture and supply revenue
$11.9M
Gross margin · GAAP
71 %
EPS · GAAP
$0.18 for both basic and diluted loss
full-year 2026 outlook
$46 to $50

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenuesGAAP$13.8M–38%
Manufacture and supply revenueGAAP$11.9M––
License and royalty revenueGAAP$1.3M––
Manufacture and supply expensesGAAP$4.02M––
Gross Margin on total revenueGAAP71 %––
Non-GAAP adjusted manufacture and supply expensesnon-GAAP$3.84M––
Non-GAAP Gross Margin on total revenuenon-GAAP72 %––
Research and development expensesGAAP$4M––
Non-GAAP adjusted research and development expensesnon-GAAP$3.63M––
Selling, general and administrative expensesGAAP$14.1M––
Non-GAAP adjusted selling, general and administrative expensesnon-GAAP$11.53M––
Total costs and expensesGAAP$22.04M––
Non-GAAP adjusted costs and expensesnon-GAAP$19.01M––
Loss from operationsGAAP−$8.22M––
Loss on extinguishment of debtGAAP$(11.7 million)––
Interest expenseGAAP−$2.81M––
Interest expense related to royalty obligationsGAAP−$972K––
Interest expense related to the sale of future revenueGAAP−$61K––
Interest income and other income, netGAAP$882K––
Net loss before income taxesGAAP−$22.86M––
Net lossGAAP$22.9M––
Basic and diluted loss per shareGAAP$0.18 for both basic and diluted loss per share––
Non-GAAP adjusted EBITDA lossnon-GAAP$5.2M––
Net loss excluding the impact of the one-time recognition of the loss on extinguishment on the Company's 13.5% Notesother$11.2M––
Six Months Ended June 30 revenuesGAAP$28.27M––
Six Months Ended June 30 loss from operationsGAAP−$12.43M––
Six Months Ended June 30 net lossGAAP−$30.92M––
Six Months Ended June 30 basic and diluted loss per shareGAAP$(0.25) (in dollars per share)––
Six Months Ended June 30 non-GAAP adjusted EBITDAnon-GAAP−$6.96M––

Segments

SegmentRevenueq/qy/y
Manufacture and supply revenuePrimarily due to increases in Suboxone revenues, partially offset by lower Ondif revenues.$11.9M––
License and royalty revenuePrimarily due to royalty revenue from Zevra.$1.3M––

full-year 2026 outlook

  • Revenue$46 to $50
  • NoteNon-GAAP adjusted EBITDA loss (in millions): $35 to $30
  • NoteResubmit the Anaphylm New Drug Application (NDA) in the third quarter of 2026.
  • NoteSubmit regulatory applications in Canada by the end of 2026.
  • NoteSubmit regulatory applications in the European Union in the first quarter of 2027.
  • NoteExisting clinical data is expected to support regulatory submissions in additional markets in 2027, including the United Kingdom.
  • NoteLibervant is expected to become eligible for full approval following the expiration in January 2027 of the orphan drug exclusivity protecting another company's FDA-approved product.

What drove it

  • The Company completed the human factors validation study and pharmacokinetic study required to address deficiencies identified in the January 30, 2026 Complete Response Letter for Anaphylm.
  • Based on preliminary data, the Anaphylm PK study met its primary endpoints. No administration errors were observed in the self-administration arm, and there were no serious adverse events or events that led to study drug discontinuation.
  • The Company manufactured approximately 48 million doses in the second quarter 2026, compared to approximately 37 million doses in the second quarter 2025.
  • Manufacture and supply revenue increased primarily due to increases in Suboxone revenues, partially offset by lower Ondif revenues.
  • License and royalty revenue increased primarily due to royalty revenue from Zevra.
  • R&D expense declined primarily because of lower development and manufacturing costs associated with Anaphylm, partially offset by increased preclinical costs.
  • GAAP gross margin on total revenue was 71 %, compared with 54 % in the second quarter of 2025.

Concerns

  • The Company recognized a one-time loss on extinguishment of debt of $11.7 million in the second quarter 2026.
  • Selling, general and administrative expenses increased to $14.1 million from $12.7 million, including higher legal fees of approximately $2.1 million, higher severance costs of approximately $1.4 million, higher personnel costs of approximately $0.9 million, and higher share-based compensation expenses of approximately $0.3 million.
  • Interest income and other income, net declined to $882 (in thousands) from $2,096 (in thousands).
  • The Company will request an expedited review upon Anaphylm NDA resubmission, though no shortened or expedited review timeline can be guaranteed.
  • Libervant remains tentatively approved in the United States for epilepsy patients ages 12 years and older and is expected to become eligible for full approval following the expiration in January 2027 of orphan drug exclusivity protecting another company's FDA-approved product.
  • The Company identifies Suboxone as a sunsetting product that accounts for a substantial part of current operating revenue.

What to watch

  • Resubmission of the Anaphylm NDA in the third quarter of 2026 and the FDA's response, including any decision on expedited review.
  • Anaphylm regulatory applications in Canada by the end of 2026 and in the European Union in the first quarter of 2027.
  • Commercial readiness and payer engagement for a potential focused, allergist-first Anaphylm launch.
  • Further development of AQST-108 in dermatologic inflammatory indications, including atopic dermatitis.
  • The January 2027 expiration of the orphan drug exclusivity affecting potential Libervant full approval for patients ages 12 years and older.
  • Execution against full-year 2026 guidance of total revenue of $46 to $50 and non-GAAP adjusted EBITDA loss of $35 to $30.

Balance sheet and cash flow

  • Cash and cash equivalents were $98.5 million as of June 30, 2026.
  • Cash and cash equivalents: $98,490 (in thousands) at June 30, 2026, compared with $121,169 (in thousands) at December 31, 2025.
  • Trade and other receivables, net: $9,326 (in thousands) at June 30, 2026, compared with $17,763 (in thousands) at December 31, 2025.
  • Inventories: $7,366 (in thousands) at June 30, 2026, compared with $6,169 (in thousands) at December 31, 2025.
  • Total assets: $132,104 (in thousands) at June 30, 2026, compared with $160,425 (in thousands) at December 31, 2025.
  • Debt, current: $32 (in thousands) at June 30, 2026, compared with $9,994 (in thousands) at December 31, 2025.
  • Debt, long-term, net: $50,654 (in thousands) at June 30, 2026, compared with $27,519 (in thousands) at December 31, 2025.
  • Royalty obligations, net: $27,835 (in thousands) at June 30, 2026, compared with $25,941 (in thousands) at December 31, 2025.
  • Liability related to the sale of future revenue, net: $61,168 (in thousands) at June 30, 2026, compared with $62,023 (in thousands) at December 31, 2025.
  • Total liabilities: $188,690 (in thousands) at June 30, 2026, compared with $194,087 (in thousands) at December 31, 2025.
  • Total stockholders’ deficit: $(56,586) (in thousands) at June 30, 2026, compared with $(33,662) (in thousands) at December 31, 2025.

Analysis

Second-quarter revenue increased 38% to $13.8 million from $10.0 million. Growth was led by manufacture and supply revenue of $11.9 million, primarily reflecting higher Suboxone revenues, partly offset by lower Ondif revenues. License and royalty revenue reached $1.3 million, with the increase primarily due to Zevra royalty revenue. The manufacturing operation produced approximately 48 million doses, compared with approximately 37 million doses in the prior-year quarter.

Margin and operating trends improved despite higher overhead. GAAP gross margin on total revenue was 71 %, compared with 54 %, while non-GAAP gross margin was 72 %, compared with 57 %. Manufacture and supply expenses declined to $4,017 (in thousands) from $4,561 (in thousands), and R&D expenses declined to $4.0 million from $4.1 million. Selling, general and administrative expenses rose to $14.1 million from $12.7 million, driven by higher legal fees, severance costs, personnel costs and share-based compensation, partly offset by lower commercial spending and lower regulatory and licensing fees.

The GAAP net loss widened to $22.9 million, or $0.18 for both basic and diluted loss per share, from $13.5 million, or $0.14 for both basic and diluted loss per share. The principal factor was the $11.7 million one-time loss on extinguishment of debt. Excluding that item, net loss was $11.2 million. Non-GAAP adjusted EBITDA loss improved to $5.2 million from $9.3 million. Cash and cash equivalents were $98.5 million as of June 30, 2026, while long-term debt, net was $50,654 (in thousands) and the stockholders’ deficit was $(56,586) (in thousands).

The strategic focus remains Anaphylm. The Company completed the human factors validation and PK studies intended to address the January 30, 2026 CRL, stated that preliminary PK data met primary endpoints, and reaffirmed a Q3 2026 NDA resubmission. The Company is conducting medical-affairs, market-access and launch-preparation activities while pursuing filings in Canada by the end of 2026 and the European Union in the first quarter of 2027. FDA review timing remains a central uncertainty because the Company will request, but cannot guarantee, expedited review.

AQST-108 adds an earlier-stage pipeline option following completion of a Phase 1 study in androgenic alopecia with no safety concerns observed, while the program expands into atopic dermatitis and other dermatologic inflammatory indications. Libervant remains subject to its tentative-approval status and the January 2027 expiration of another company's orphan drug exclusivity. Financial guidance was unchanged at total revenue of $46 to $50 and non-GAAP adjusted EBITDA loss of $35 to $30 for full-year 2026.

Management, verbatim

As we bring Anaphylm to market, if approved by the FDA, we believe we can be instrumental in driving conversion in the allergist office and, ultimately, the broader market.

Daniel Barber, President and Chief Executive Officer of Aquestive Therapeutics

As we prepare to resubmit our application to the FDA in the coming weeks, our full attention will be to prepare for a focused, allergist-first launch of Anaphylm as quickly as possible, if approved by the FDA.

Daniel Barber, President and Chief Executive Officer of Aquestive Therapeutics

Although AQST-108 is still in early-stage development, we are encouraged by the emerging data and plan on continuing to advance the program as we look towards 2027.

Daniel Barber, President and Chief Executive Officer of Aquestive Therapeutics

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported quarterly financial metrics
  • Operating cash flow
  • Free cash flow
  • Capital expenditures
  • Share repurchases
  • Dividends
  • GAAP gross-margin outlook
  • Operating-expense outlook
  • Tax-rate outlook
  • Previous-release outlook for comparison with actual results

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about AQST earnings dates

When is Aquestive Therapeutics's next earnings date?
AlphAI has no date for AQST yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.